Retinochoroidopathy after intravitreal anti-VEGF treatment;Retinochoroidopathie nach intravitrealer Anti-VEGF-Behandlung

Ophthalmologe

Volumn 106, Issue 8, 2009, Pages 729-734

  Maier, Dr ^a   Feucht, N ^a   Lanzl, I ^a   Kook, P ^a   Lohmann, C P ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Injection of bevacizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; BEVACIZUMAB; FLUOCORTOLONE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHORIORETINITIS; DRUG ANTAGONISM; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MALE; TREATMENT OUTCOME; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHORIORETINITIS; FLUOCORTOLONE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 70349873625     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-008-1839-3     Document Type: Article

References (22)

1. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372
2. Bakri SJ, Snyder MR, Reid JM et al. (2007) Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology 114: 855-859
3. Chan CK, Meyer CH, Gross JG et al. (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27(5): 541-551
4. Emerson MV, Lauer AK, Flaxel CJ et al. (2007) Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration. Retina 27(4): 439-444
5. Fung AE, Rosenfeld PJ et al. (2007) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344-1349
6. Göbel W (2008) White-Dot-Syndrome. Ophthalmologe 105(1): 91-109
7. Heiduschka P, Fietz H, Hofmeister S et al. (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48(6): 2814-2823
8. Joseph DP, Daniel P, Brantley MA, Grand MG. RAND (2003) Serpiginouslike choroiditis in a patient with cardiac sarcoidosis. Retina 23(1): 116
9. Kiss C, Michels S et al. (2006) Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26(8): 877-881
10. Kook D, Wolf A, Neubauer AS et al.(2007) Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: Frequency and progress. Ophthalmologe [Epub ahead of print]
11. Ladewig MS, Ziemssen F, Jaissle G et al. (2006) Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103(6): 463-470
12. Manzano RP, Peyman GA, Khan P et al. (2006) Testing intravitreal toxicity of bevacizumab (avastin) Retina 26: 257-261
13. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiological findings after intravitreal bevacizumab (avastin) treatment. Retina 26: 270-274
14. Mennel S, Callizo J, Schmidt JC, Meyer CH (2007)Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (avastin) injections. Acta Ophthalmol Scand 85: 689-690 49
15. Meyer CH, Ziemssen F, Heimann H (2008) Intravitreale Injektion. Ophthalmologe 105(2): 143-157
16. Monnet D, Levinson RD, Holland GN et al. (2007) Longitudinal cohort study of patients with birdshot chorioretinopathy. III. Macular imaging at baseline. Am J Ophthalmol 144(6): 818-828
17. Ralph D, Levinson MD et al. (2006) Research criteria for the diagnosis of birdshot chorioretinopahty: Results of an international consensus conference. Am J Ophthalmol 141(1): 185-187
18. Ryan SJ, Maumenee AE (1980) Birdshot retinochoroidopathy. Am J Ophthalmol 89(1): 31-45
19. Shahar J, Avery RL, Heilweil G et al. (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin). Retina 26: 262-269
20. Spalton DJ, Hitchings RA, Hunter PA (2006) Atlas der Klinischen Ophthalmologie 304-308
21. Weinberger AW, Thiel M, Mohammadi B et al. (2007) Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 144(2): 294-296
22. Ziemssen F, Bartz-Schmidt KU et al. (2006) (Neben-) Wirkungen der VEGF-Inhibition. Ophthalmologe 103(6): 484-491